Technology that delivers substantial improvements in Infection Prevention and Control has been rapidly adopted by healthcare facilities overseas, however, it has yet to be adopted at scale in Australia and New Zealand. It makes you wonder why not?
Back in 2017, Royal Manchester Childrens Hospital introduced Surfacide UV-C Disinfection technology as part of its ongoing effort to combat Healthcare Associated Infections (HAI’s). The hospital deployed four UV-C disinfection systems (12 emitters) thoughout the hospital to protect patients and staff.
Surfacide continues to be integral to Royal Manchester’s Infection Prevention and Control Strategy today. In 2021, an 8-month study was commenced in a busy oncology unit that had evidence of a number of acquisitions within their patient group. A research study involving swabbing of patient areas pre and post clean and completing a comparative study against a “Soap and Water” or ChlorClean versus Surfacide was completed using a recognised microbiology laboratory. The study concluded that Surfacide UV-C disinfection was able to significantly reduce bacterial contamination in both patient rooms and common areas with a single automated disinfection cycle using 3 emitters. With its daily use of Surfacide, Royal Manchester has been recognised as one of Surfacides Top 10 users worldwide.
As we head for our third Omicron wave in Australia, no doubt our hospitals are going to be placed under enormous pressure and the likelihood of COVID infections acquired in hospitals will increase, alongside of the many other infections acquired in hospitals. Back in May we absorbed the enormity of the problem from an article in the Sydney Morning Herald that highlighted these startling facts:
- 160,000 infections acquired in Australian hospitals each year, but health departments are only required to publicly report on staphylococcus aureus bloodstream infections (“golden staph”)
- 20% of all COVID infections came from hospitals
- People die from infections acquired in hospitals that otherwise wouldn’t have died.
So, with Surfacide UV-C scientifically proven to reduce SARS-CoV-2 (the virus that causes COVID-19) on hard surfaces and proven to disinfect colonised surfaces by reducing many bacteria and viruses in a single cycle, you would think that many Australian and New Zealand hospitals would be joining the 500+ facilities worldwide employing this advanced technology to fight infections.
Not all UV is the same
Perhaps attitudes towards UV-C as a technology are somewhat negative? There is a lot of misinformation out there and products that are not fit for purpose in the use cases described. However, as we have seen, Surfacide’s efficacy is scientifically proven and it’s the world’s only patented triple emitter ‘robotic’ UVC system currently available on the market, providing optimal efficiency and flexibility in the ongoing fight against viruses and other hospital-acquired infections (HAIs)
Cost should not be a barrier
Given the sophistication of this technology, cost could be perceived as another barrier to purchase, however with pricing plans enabling facilities to implement Surfacide as part of their disinfection regime as an operating expense, without the need for a capital purchase, this is perception versus reality. This model is proving attractive as facilities determine how to best integrate Surfacide into their current operating model. And with a single HAI from multi-resistance organisms increasing a length of stay by up to 30 days and costing upwards of $60k, what price to we put on the physical and emotional impact for the patient and their families and financially for the hospital, health funds and the community as a whole?
Improving patient satisfaction
In the US where Surfacide originates, some hospitals have been using Surfacide to positively impact their HCAHPS scores. HCAHPS scores are used to enable objective comparisons of hospitals across a variety of metrics, inform healthcare consumers about the relative standard of care at each facility and create incentives for hospitals and healthcare organizations to compete on patient engagement and satisfaction.
Given the positive impact in the US, perhaps hospitals in Australia could positively impact results in their Australian Hospital Patient Experience Question Set (AHPEQS) survey (used to ask recent patients about their experiences of treatment and care) by using Surfacide?
Perhaps it’s time to consider Surfacide as part of your infection prevention and control strategy? We will show you just how easily it can be introduced. Contact us here.